The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

British Journal of Dermatology

Volumn 167, Issue 5, 2012, Pages 1145-1152

  Tsai, T F ^a   Ho, V ^b   Song, M ^c   Szapary, P ^c   Kato, T ^d   Wasfi, Y ^c   Li, S ^e   Shen, Y K ^e   Leonardi, C ^f  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Department of Immunology LLC ^*  (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e Janssen Pharmaceutical KK   (Japan)

^f SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INTERLEUKIN 12; INTERLEUKIN 23; ISONIAZID; PLACEBO; QUANTIFERON; TUBERCULIN; UNCLASSIFIED DRUG; USTEKINUMAB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; LATENT TUBERCULOSIS; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT OUTCOME; TUBERCULIN TEST;

ADULT; ANTIBODIES, MONOCLONAL; ANTITUBERCULAR AGENTS; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; ISONIAZID; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TUBERCULIN TEST;

EID: 84868108815     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11142.x     Document Type: Article

References (33)

1. World Health Organization. Global Tuberculosis Control 2011. Available at: http://www.who.int/tb/publications/global-report/en/index.html (last accessed 21 July 2012).
2. World Health Organization. Media Centre, Tuberculosis Fact Sheet No 104 (March 2012). Available at: http://www.who.int/mediacentre/factsheets/fs104/en/ index.html (last accessed 21 July 2012).
3. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375: 1920-37.
4. World Health Organization Regional Office for South East Asia. Communicable Diseases Department. Tuberculosis. TB/HIV. Available at: http://www.searo.who.int/en/section10/section2097/section2129.htm (last accessed 21 July 2012).
5. Doherty SD, van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59: 209-17.
6. Flynn JL, Chan J,. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-129.
7. Germann T, Rude E,. Interleukin-12. Int Arch Allergy Immunol 1995; 108: 103-12.
8. D'Elios MM, Del Prete G, Amedei A,. Targeting IL-23 in human diseases. Expert Opin Ther Targets 2010; 14: 759-74.
9. O'Quinn DB, Palmer MT, Lee YK, Weaver CT,. Emergence of the Th17 pathway and its role in host defense. Adv Immunol 2008; 99: 115-63.
10. Filipe-Santos O, Bustamante J, Chapgier A, et al. Inborn errors of IL-12/23- and IFN-γ-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 2006; 18: 347-61.
11. Leonardi C, Kimball A, Papp K, et al.; for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1165-74.
12. Papp KA, Langley RG, Lebwohl M, et al.; for the PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
13. Griffiths CEM, Strober BE, van de Kerkhof P, et al.; for the ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
14. Tsai TF, Ho JC, Song M, et al.; on behalf of the PEARL Investigators. Efficacy and safety of ustekinumb for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011; 63: 154-63.
15. Igarashi A, Kato T, Kato M, et al.; the Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242-52.
16. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000; 49: 1-51.
17. Nolan CM, Goldberg SV, Buskin SE,. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-18.
18. PDR Network, LLC. Isoniazid. Available at: http://www.pdr.net/drugpages/ concisemonograph.aspx?concise=1708 (last accessed 21 July 2012).
19. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for Industry, Drug-Induced Liver Injury: Premarketing Clinical Evaluation (2009) Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM174090.pdf (last accessed 21 July 2012).
20. Tsai T-F, Chiu H-Y, Song M, Chan D,. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. Br J Dermatol. 2012. Epub ahead of print 20 Jul 2012. doi: 10.1111/j.1365.2133.2012.11162.x.
21. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-50.
22. Hernandez C, Cetner AS, Jordan JE, et al. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 2008; 59: 363-80.
23. Keane J,. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005; 44: 714-20.
24. Gardam MA, Keystone EC, Menzies R, et al.; BIOBADASER GROUP Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55.
25. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al., Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-77.
26. Gomez-Reino JJ, Carmona L, Descalzo MÁ,; for the BIOBADASER Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-61.
27. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010; 36: 1185-206.
28. Perlmutter A, Mittal A, Menter A,. Tuberculosis and tumour necrosis factor-α inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009; 160: 8-15.
29. Sánchez-Moya A, Dauden E,. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. J Eur Acad Dermatol Venereol 2011; 25: 730-3.
30. Chiu HY, Hsueh PR, Tsai TF,. Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 2011; 164: 553-9.
31. Haroon M, Martin U, Devlin J,. High incidence of intolerance to tuberculosis chemoprophylaxis. Rheumatol Int 2012; 32: 33-7.
32. Bray M-G, Poulain C, Dougados M, Gossec L,. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment. Joint Bone Spine 2010; 77: 135-41.
33. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-7.